Aussie Groups Appeal Myriad Win Of Patent Of Cancer-Risk Gene
This article was originally published in PharmAsia News
Executive Summary
Myriad Genetics faces an appeal of its recent victory in an Australian court against a challenge of its patents for genes associated with higher risks for breast and ovarian cancers.